Ertugliflozin tied to improved glycemic control in T2DM

February 20, 2018

(HealthDay)—For adults with inadequately controlled type 2 diabetes, ertugliflozin treatment is associated with improved glycemic control over 52 weeks, according to a study published online Feb. 8 in Diabetes, Obesity and Metabolism.

Ronnie Aronson, M.D., from LMC Diabetes & Endocrinology in Ontario, and colleagues conducted a phase III randomized trial to examine the efficacy and safety of ertugliflozin monotherapy in adults with inadequately controlled type 2 despite diet and exercise. The study comprised a 26-week placebo-controlled period where 461 participants received placebo or ertugliflozin (5 or 15 mg/day) and a second 26-week period in which in the had blinded metformin added.

The researchers found that the mean change in glycated hemoglobin (HbA1c) from baseline to week 52 was −0.9 and −1 percent in the ertugliflozin 5- and 15-mg groups, respectively; the proportion of patients with HbA1c <7 percent was 25.6 and 28.5 percent, respectively, at week 52. Ertugliflozin was correlated with a reduction in fasting plasma glucose, body weight, and systolic blood pressure. In females, the incidence of genital mycotic infections (GMIs) was significantly higher in both the 5- and 15-mg ertugliflozin groups versus placebo/metformin (26.9 and 29 versus 9.9 percent); males had significantly higher GMI incidence in the 15-mg group (7.8 versus 1.2 percent).

"Ertugliflozin treatment over 52 weeks improved and reduced body weight and systolic blood pressure but increased GMIs," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Pfizer and Merck & Co., which funded the study.

Explore further: Addition of DPP4i to AGI reduces HbA1c in T2DM

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Addition of DPP4i to AGI reduces HbA1c in T2DM

October 5, 2017
(HealthDay)—For patients with type 2 diabetes mellitus (T2DM), inadequately controlled with alpha-glucosidase inhibitors (AGIs), the addition of a dipeptidyl peptidase-4 (DPP4) inhibitor (DPP4i) is associated with a greater ...

Ranolazine added to glimepiride cuts HbA1c in T2DM

January 18, 2016
(HealthDay)—For patients with type 2 diabetes on background glimepiride therapy, but not metformin, addition of ranolazine is associated with a significant reduction in hemoglobin A1c (HbA1c), according to research published ...

Diacerein reduces mean hemoglobin A1c levels in T2DM

August 25, 2017
(HealthDay)—An immune-modulator anti-inflammatory drug, diacerein, reduces the mean hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes, according to a study published online Aug. 17 in Diabetes Care.

Imeglimin beneficial as add-on to metformin in T2DM

December 14, 2012
(HealthDay)—For patients with type 2 diabetes inadequately controlled by metformin alone, addition of the new oral anti-diabetes agent imeglimin improves glycemic control with good tolerability and safety, according to ...

Liraglutide tops lixisenatide as add-on to metformin in T2DM

June 28, 2016
(HealthDay)—For patients with type 2 diabetes taking metformin, add-on liraglutide is more effective than lixisenatide for improving glycemic control, according to a study published online June 16 in Diabetes Care.

Glucagon receptor antagonist ups blood pressure in T2DM

February 23, 2017
(HealthDay)—For patients with type 2 diabetes, once-daily treatment with the glucagon receptor antagonist LY2409021 is associated with increases in ambulatory blood pressure (BP), according to a study published online Feb. ...

Recommended for you

Belly fat promotes diabetes under orders from liver

March 21, 2018
The fat that builds up deep in the abdomen—more than any other type of body fat—raises the risk of insulin resistance and type 2 diabetes. Researchers have known that abdominal fat becomes dangerous when it becomes inflamed ...

Consuming low-calorie sweeteners may predispose overweight individuals to diabetes

March 18, 2018
Consumption of low-calorie sweeteners could promote metabolic syndrome and predispose people to prediabetes and diabetes, particularly in individuals with obesity, a new study on human fat-derived stem cells and fat samples ...

Are high blood glucose levels an effect rather than the cause of diabetes?

March 15, 2018
Insulin resistance and elevated blood glucose levels are considered to be the cause of type 2 diabetes. However, scientists from the German Cancer Research Center (DKFZ) and Heidelberg University Hospital have now provided ...

Smoking linked with higher risk of type 2 diabetes

March 15, 2018
The prevalence of diabetes has increased almost 10-fold in China since the early 1980s, with one in 10 adults in China now affected by diabetes. Although adiposity is the major modifiable risk factor for diabetes, other research ...

Social support and machine learning are at the core of a student-developed app for people with diabetes

March 14, 2018
Diabetes is the seventh leading cause of death in the U.S., and nearly 10 percent of the population suffers from this chronic disease, according to the Centers for Disease Control and Prevention.

Toxic proteins and type 2 diabetes

March 9, 2018
Nearly a half-billion people worldwide live with type 2 diabetes. Yet despite the disease's sizeable and increasing impact, its precise causes remain murky. Current scientific thinking points to two key processes: insulin ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.